We report the in vitro drugs interaction by the resazurin drugs combination microtiter assay (REDCA) of amoxicillin (AMO)/clavulanate (CLAV) with isoniazid (INH), ethambutol (EMB), and rifampicin (RIF) against susceptible and resistant Mycobacterium tuberculosis isolates. The addition of AMO/CLAV to classical antituberculosis drugs should be explored as a promising alternative for the treatment of resistant tuberculosis (TB).
Pagliotto, A. D. F., Caleffi-Ferracioli, K. R., Lopes, M. A., Baldin, V. P., Leite, C. Q. F., Pavan, F. R., … Cardoso, R. F. (2016). Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination. Journal of Microbiology, Immunology and Infection, 49(6), 980–983. https://doi.org/10.1016/j.jmii.2015.08.025